Business

Feliza Mirasol is the science editor for 

Articles

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

The merger agreement is valued at approximately $1.1 billion.

Avid Bioservices Acquired by GHO Capital Partners and Ampersand Capital Partners

With DKK 600 million (US$87.4 million) in funding from the Novo Nordisk Foundation, the new supercomputer offers the potential to accelerate innovation in drug discovery.

Denmark’s First AI Supercomputer for Drug Discovery Now Operational Under Novo Nordisk Foundation Commitment

The collaboration aims to advance clinical development of a Phase I drug candidate, MRT-6160, and to explore other therapeutic opportunities across multiple indications.

Novartis and Monte Rosa Therapeutics Form $2.1 Billion Global License Agreement for MGD-based Therapeutics

Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments. 

Merck Acquires Modifi Biosciences

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

REGiMMUNE and Kiji Therapeutics to Merge

Merck will deploy Mestag’s proprietary RAFT platform to investigate the pathogenic role that fibroblasts play in inflammatory diseases.

Merck to Collaborate with Mestag Therapeutics in $1.9 Billion Deal to Identify Novel Targets for Inflammatory Diseases

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

This Behind the Headlines news roundup panel discussion covers news items such as the weight loss drugs battle between Novo Nordisk and Eli Lilly, entering new territory through Lilly’s partnership with HAYA Therapeutics and long non-coding sequence mining. There was much discussion on how the inflation reduction act and Medicare price controls may or may not pertain—given the uncertainty around the presidential election results, and subsequent policy directions. The Centers for Disease Control making cost free COVID-19 diagnostics and therapies available was also evaluated. 

Behind the Headlines: Weight Loss Drugs; Price Controls; and Free COVID Therapies

The completed acquisition of Morphic expands Lilly's immunology pipeline with Morphic's oral integrin therapies for treating inflammatory bowel disease.

Completion of $3.2 Billion Morphic Acquisition Expands Lilly’s IBD Portfolio

Merck, known as MSD outside of the United States and Canada, will gain CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical in a  deal potentially worth up to $1.3 billion. 

Business News